Adverse effects of acetylcholinesterase inhibitors

Clinical Geriatrics

Volumn 19, Issue 1, 2011, Pages 27-30

  Patel, Birju B ^a,b   Holland, N Wilson ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ABDOMINAL PAIN; ABNORMAL DREAMING; AGGRESSION; AGITATION; ANOREXIA; ARTICLE; ASTHENIA; BLOOD CHEMISTRY; BRADYCARDIA; BRAIN ISCHEMIA; CHILL; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DIARRHEA; DIASTOLIC DYSFUNCTION; DIVERTICULOSIS; DIZZINESS; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; ESOPHAGUS RUPTURE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HALLUCINATION; HEALTH CARE COST; HEART ARRHYTHMIA; HEPATITIS; HUMAN; INSOMNIA; LEG CRAMP; LIVER DYSFUNCTION; MEDICAL HISTORY; MYASTHENIA; NAUSEA; ORTHOSTATIC HYPOTENSION; RHINITIS; RHINORRHEA; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SEIZURE; SIDE EFFECT; SYNCOPE; SYSTOLE; THYROID HORMONE BLOOD LEVEL; TREATMENT PLANNING; TREMOR; URINE INCONTINENCE; VOMITING;

EID: 79951915120     PISSN: 10951598     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ferri CP, Prince M, Brayne C, et al; Alzheimer's Disease International. Global prevalence of dementia: A Delphi consensus study. Lancet 2005;366(9503):2112-2117. (Pubitemid 41797645)
2. Alzheimer's Association. 2010 Alzheimer's disease facts and figures. http://www.alz.org/ documents-custom/report-alzfactsfigures2010.pdf. Accessed December 13, 2010.
3. Census bureau reports world's older population projected to triple by 2050 [press release]. U.S. Census Bureau Newsroom. June 23, 2009.
4. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;(1):CD005593.
5. Clark CM, Karlawish JH. Alzheimer disease: Current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med 2003;138(5):400-410. (Pubitemid 36262651)
6. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271(13):992-998. (Pubitemid 24099919)
7. Morden NE, Zerzan JT, Larson EB. Alzheimer's disease medication: Use and cost projections for Medicare Part D. J Am Geriatr Soc 2007;55(4):622-624. (Pubitemid 46496577)
8. Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999;52(6):1138-1145. (Pubitemid 29177912)
9. Hauber AB, Gnanasakthy A, Mauskopf JA. Savings in the cost of caring for patients with Alzheimer's disease in Canada: An analysis of treatment with rivastigmine. Clin Ther 2000;22(4):439-451. (Pubitemid 30304795)
10. Ames D, Kaduszkiewicz H, van den Bussche H, Zimmermann T, Birks J, Ashby D. For debate: Is the evidence for the efficacy of cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease convincing or not? Int Psychogeriatr 2008;20(2):259-292. Published Online: February 6, 2008. (Pubitemid 351230236)
11. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology 1996;47(4):876-883.
12. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50(1):136-145.
13. Cummings JL. Use of cholinesterase inhibitors in clinical practice: Evidence-based recommendations. Focus 2004;2(2):239-252.
14. Cummings JL. Use of cholinesterase inhibitors and clinical practice: Evidence-based recommendations. Am J Geriatr Psychiatry 2003;11(2):131-145. (Pubitemid 36254187)
15. Agronin ME. Alzheimer Disease and Other Dementias: A Practical Guide. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2008.
16. Physicians' Desk Reference. 2011. 65th ed. Montvale, NJ: PDR Network; 2010.
17. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002;(127):45-63. (Pubitemid 34778530)
18. Gauthier S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer 's disease: Epidemiology and management. Drugs Aging 2001;18(11):853-862. (Pubitemid 34073130)
19. Novartis Exelon labeling update reflects report of esophageal rupture. The Pink Sheet 2001;63:24.
20. Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: A population-based cohort study. Arch Intern Med 2009;169(9):867-873.
21. Hashimoto M, Imamura T, Tanimukai S, Kazui H, Mori E. Urinary incontinence: An unrecognized adverse effect with donepezil. Lancet 2000;356(9229):568. (Pubitemid 30611868)
22. Mimica N, Presecki P. Side effects of approved antidementives. Psychiatr Danub 2009;21(1):108-113.
23. Graff MJ, Adang EM, Vernooij-Dassen MJ, et al. Community occupational therapy for older patients with dementia and their care givers: Cost effectiveness study. BMJ 2008;336(7636):134-138. Published Online: January 2, 2008. (Pubitemid 351216996)
24. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann Intern Med 2008;148(5):379-397. (Pubitemid 351665469)
25. Qaseem A, Snow V, Cross JT Jr, et al; American College of Physicians/American Academy of Family Physicians Panel on Dementia. Current pharmacologic treatment of dementia: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008;148(5):370-378. (Pubitemid 351665468)
26. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease. A meta-analysis. JAMA 2003;289(2):210-216. (Pubitemid 36068709)
27. Lindstrom HA, Smyth KA, Sami SA, et al. Medication use to treat memory loss in dementia: Perspectives of persons with dementia and their caregivers. Dementia 2006;5(1):27-50.